Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 10/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | ACLY | P53396 | 1/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | LOX | P28300 | 1/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.37 |
| ▸ | EDNRB | P24530 | 1/20 | 0.37 |
| ▸ | EDNRA | P25101 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29415408 | 0.84 | PTGS2 (0.61) | PTGS2L3MBTL1PTGS1ACLYMAOA | |
| SCHEMBL937206 | 0.84 | PTGS2 (0.61) | PTGS2L3MBTL1PTGS1ACLYMAOA | |
| SCHEMBL2447766 | 0.82 | PTGS2 (0.64) | PTGS2L3MBTL1PTGS1ACLYLOXL2 | |
| Hydrochloric Acid SCHEMBL7352630 | 0.82 | PTGS2 (0.59) | PTGS2L3MBTL1PTGS1ACLYLOXL2 | |
| SCHEMBL8658514 | 0.80 | PTGS2 (0.62) | PTGS2PTGS1ACLYMAOALOX | |
| SCHEMBL4198455 | 0.76 | PTGS2 (0.62) | PTGS2L3MBTL1PTGS1ACLY | |
| SCHEMBL29700169 | 0.76 | PTGS2 (0.52) | PTGS2L3MBTL1PTGS1ACLY | |
| SCHEMBL8770199 | 0.73 | PTGS2 (0.53) | PTGS2L3MBTL1PTGS1ACLY | |
| SCHEMBL4629803 | 0.72 | PTGS2 (0.47) | PTGS2L3MBTL1AKR1B1EDNRBEDNRA | |
| SCHEMBL9538025 | 0.72 | PTGS2 (0.52) | PTGS2L3MBTL1PTGS1ACLYLOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080058349-A1 | New Compounds 318 | ASTRAZENECA AB (SE) | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058349-A1 | New Compounds 318 | PSEN2, PSEN1, MAPT | PTGS2 2935/4885L3MBTL1 4579/4885PTGS1 2351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.